Tau aggregation and its interplay with amyloid-β
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Neurofibrillary tangles and amyloid plaques constitute the hallmark brain lesions of Alzheimer's disease (AD) patients. Tangles are composed of fibrillar aggregates of the microtubule-associated protein tau, and plaques comprise fibrillar forms of a proteolytic cleavage product, amyloid-β (Aβ). Although plaques and tangles are the end-stage lesions in AD, small oligomers of Aβ and tau are now receiving increased attention as they are shown to correlate best with neurotoxicity. One key question of debate, however, is which of these pathologies appears first and hence is upstream in the pathocascade. Studies suggest that there is an intense crosstalk between the two molecules and, based on work in animal models, there is increasing evidence that Aβ, at least in part, exerts its toxicity via tau, with the Src kinase Fyn playing a crucial role in this process. In other experimental paradigms, Aβ and tau have been found to exert both separate and synergistic modes of toxicity. The challenge, however, is to integrate these different scenarios into a coherent picture. Furthermore, the ability of therapeutic interventions targeting just one of these molecules, to successfully neutralize the toxicity of the other, needs to be ascertained to improve current therapeutic strategies, such as immunotherapy, for the treatment of AD. Although this article is not intended to provide a comprehensive review of the currently pursued therapeutic strategies, we will discuss what has been achieved by immunotherapy and, in particular, how the inherent limitations of this approach can possibly be overcome by novel strategies that involve single-chain antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of glial cells may provide a link between the initial Aβ aggregation and the later development of tau aggregates,40”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxcity), suggesting that the presence of both pathological features are important to replicate the toxicity that occurs in human AD [106].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 2×
“Evidently, no mouse model is capable of fully recapitulating the neuropathological spectrum of the disease [72].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · cited 1×
“connected brain regions [15].”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cited by
Items 301–360 of 360
Dabas, A., Priyadarshi, N., Goyal, D., Singhal, N. K., & Goyal, B. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c06148 · Cited by 1
Blood-based biomarkers and early diagnosis of Alzheimer’s disease
Cui, Z., Li, G., Wei, S., Cheng, Q., Yu, Q., Zong, S., Zhang, P., Chen, H., Yu, S., Wu, S., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00759 · Cited by 1
“Furthermore, Aβ oligomers promote the abnormal phosphorylation of tau proteins, forming NFTs, another pathological hallmark of AD (Nisbet et al., 2015).”
Reverse allostasis in biological systems: Minimal conditions and implications
Rezaei‐Ghaleh, N., Bakhtiari, D., & Rashidi, A. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.05.025 · Cited by 1
Ultrasound as a treatment modality for neurological diseases
Leinenga, G., Nisbet, R. M., & Götz, J. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01013 · Cited by 1
Self-citationThe comprehensive mechanistic insight into the effects of vitamin D on dementia – a review
Jafarzadeh, J., Payahoo, L., Yousefi, M., & Barzegar, A. (2021) · Nutrition & Food Science · doi:10.1108/nfs-08-2021-0256 · Cited by 1
Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia
Joshi, D. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998279875240216093902 · Cited by 1
Myakotnykh, V. S., Sidenkova, A. P., Bazarnyi, V. V., Мельник, А. А., Уразаева, А. Т., & Хилюк, Д. А. (2022) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2022-1(114)-40-45 · Cited by 1
Fitzsimons, L. A., Atif-Sheikh, M., Mueth, M. G., Rice, M., Howell, G. R., & Harrison, B. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.24.604961 · Cited by 1
“A genetic association between CD2AP, tau-accumulation and subsequent neurotoxicity 31 have been observed using drosophila homolog cindr in a loss of function model of AD 31,32 .”
Hyper-Glycosylation as a Central Metabolic Driver of Alzheimer’s DiseasePreprint
Hawkinson, T. R., Liu, Z., Ribas, R. A., Medina, T., Nielsen, R. S., Clarke, H. A., Ma, X., Mueller, A. C., Plasencia, A. F., Shear, A. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.30.651461 · Cited by 1
Estratégias terapêuticas baseadas nos mecanismos fisiopatológicos conhecidos na Doença de Alzheimer
Janeiro, D. I. S. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Cella, R. F. (2016) · ScholarlyCommons (University of Pennsylvania)
Croft, C. L. (2016) · Research Portal (King's College London)
Bidirectional Regulation of A beta Aggregates: Focus on Therapeutic Targets for Alzheimer's Disease
Zhang, Y., & Li, J. T. (2017) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000146
Review Article Tau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow�, E., Mandelkow, E., Miller, D. S., et al. (2016)
Lundgren, J. L. (2018) · Figshare
Saeed, U. (2018) · TSpace (University of Toronto)
Adhikari, R. (2019) · Digital Commons - Michigan Tech (Michigan Technological University) · doi:10.37099/mtu.dc.etdr/891 · Cited by 1
Gut Microbiota as Signatures in Non-communicable Diseases and Mucosal Immunity
Behera, S. K., Praharaj, A. B., Chalikonda, G., Srivani, G., & Mahapatra, N. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-2017-4_11 · Cited by 1
Amyloid Beta: The Foremost Protagonist in Alzheimer's Disease
Anand, A., Sharma, N., Gulati, M., & Khurana, N. (2020) · IGI Global eBooks · doi:10.4018/978-1-7998-3441-0.ch001
Mira, H., Díez del Corral, R., & Morales, A. V. (2020) · Frontiers research topics · doi:10.3389/978-2-88963-988-5
Acupuncture and Alzheimer’s Disease
Xu, Y., Wen, G., Asakawa, T., & Xia, Y. (2022) · Springer eBooks · doi:10.1007/978-3-030-96221-0_23
Endothelin Receptors in Cerebrovascular Diseases
Briyal, S., Ranjan, A. K., & Gulati, A. (2022) · Wiley eBooks · doi:10.1002/9781119564782.ch16
Veiveris, D., Kopūstas, A., Šulskis, D., Mikalauskaitė, K., Tutkus, M., Smirnovas, V., & Žiaunys, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625672
Oresanya, I. O., Abacı, N., & Orhan, İ. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15366-2.00008-3
Early Alzheimer’s disease: Clinical overview
Selwood, J., & Coulthard, E. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-822240-9.00001-6
Tau Enhances Aggregation of S100A9 Protein and Further Association of Its Fibrils
Krasauskas, L., Veiveris, D., Žiaunys, M., Šulskis, D., Sakalauskas, A., & Smirnovas, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188961
“Further ex vivo and in vitro examinations revealed an even larger number of cross-interacting pairings, which include amyloid-beta with Tau [12,13] (related to AD), prion proteins [14] (prionopathies), and alpha-synuclein (PD) [15], as well as alpha-synuclein with Tau [16,17] and prion proteins…”
Jana, A. K., Khatua, P., & Bandyopadhyay, S. (2025) · Journal of Chemical Sciences · doi:10.1007/s12039-025-02426-2
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Figshare · doi:10.6084/m9.figshare.14538839
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390910
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390880
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Figshare · doi:10.6084/m9.figshare.14538842
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A., DeGrado, W. F., & Condello, C. (2021) · Figshare · doi:10.6084/m9.figshare.17696286
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390904
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A., DeGrado, W. F., & Condello, C. (2021) · Figshare · doi:10.6084/m9.figshare.17696280
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Figshare · doi:10.6084/m9.figshare.14538845
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390898
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390883
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390886
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390913
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390892
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390877
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Figshare · doi:10.6084/m9.figshare.14538848
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Figshare · doi:10.6084/m9.figshare.14538851
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390901
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20390907
Karim, M. R. U., Haque, S. K. L., Islam, M., Higgins, C., Selim, M., Sardar, M. N., & Du, D. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07284
Ventricular enlargement is associated with early Alzheimer’s disease pathophysiology
Hosseini, S. A., Aumont, É., Rahmouni, N., Woo, M. S., Macedo, A. C., Hall, B. J., Trudel, L., Chan, T., Arias, J. F., Wang, Y.-T., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag066
“58 Therefore, even though ventricular remodelling and A β deposition co-occur, the effects of ventricular remodelling on tau are secondary to the processes initiated by A β .”
Cho, Y. E., Kim, A., Lee, H. M., Oh, J. W., Son, S. J., Roh, H. W., Jung, Y.-S., Hong, C. H., Lee, S. Y., & Kim, K. P. (2026) · Molecular Brain · doi:10.1186/s13041-026-01294-2
Mobilisation de l'acide arachidonique et sensibilité au peptide ß-amyloïde
Thomas, M. H. (2015) · theses.fr (ABES) · doi:10.70675/904987d5zc8c8z4104z95dfz2f7e680d8be3 · Cited by 1
Eysert, F. (2019) · theses.fr (ABES) · doi:10.70675/cde90ae3z11f1z43e2z8031zae68eac45ec8 · Cited by 2
“, « l’Aβ serait le déclencheur de la MA mais Tau serait la balle », donc l’effecteur de la maladie (Bloom, 2014; Nisbet et al., 2015).”
BackgroundInfluentialChoudhury, A., Saeed, M. U., Prabha, S., & Hassan, M. I. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00097
Yang, S., Liu, H.-C., Chiu, M., Chang, J.-F., Ho, C.-S., & Lee, K.-H. (2026) · ACS Omega · doi:10.1021/acsomega.6c00355
Tau physiology and pathology: impacts on cellular structures and neurodegenerative diseases
Akbari, V., & Bahramikia, S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02328-w
“From a therapeutic perspective, lowering tau levels or inhibiting the interaction between tau and Fyn or between NMDAR and PSD-95 represents a viable strategy to disrupt excitotoxic downstream signaling (Nisbet et al. 2015).”
Li, M.-Y., Lin, Y.-Y., Wang, C., Qi, Y., Zhang, J., Ge, D., Yu, H., Zhang, H., & Bao, J. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11679-z · Cited by 1
Yang, T., Tran, K. C., Leng, A., Langness, V. F., Massa, S. M., & Longo, F. M. (2026) · Cells · doi:10.3390/cells15191822
“Previous reports show that A β promotes Fyn activation, excess phosphorylation of the Fyn substrates NR2B and tau [33,41,89,90], and tau oligomerization [33,91], all of which contribute to synaptic dysfunction.”
Mankoo, O. K., Priyadarshi, N., Singh, P. P., Goyal, B., Singhal, N. K., & Goyal, D. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d6cp01611a
Metadata
- Authors
- Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- UNSW Sydney (AU)
- Corresponding author
- Nisbet, Rebecca M.
- Götz, Jürgen
- Venue
- Acta Neuropathologica
- Published
- 2014-12-10
- Volume
- 129
- Issue
- 2
- Pages
- 207-220
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4305093
- OpenAlex
- W2007787335
- Cited by
- 359
- References
- 114
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 20 · 2023: 22 · 2022: 49 · 2021: 41 · 2020: 33 · 2019: 44 · 2018: 32 · 2017: 26 · 2016: 31 · 2015: 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP13300101932)
- National Health and Medical Research Council (1003150, 1037746)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau aggregation, amyloid-beta, Alzheimer's disease, neurofibrillary tangles, amyloid plaques, tau oligomers, amyloid-beta oligomers, neurotoxicity, Fyn, immunotherapy, single-chain antibody, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Humans, Synapses, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.